Matteo Renzulli

Prof. Matteo Renzulli

Radiology Unit, Department of Experimental Diagnostic and Specialized Medicine, S. Orsola Hospital, University of Bologna, Bologna, Italy.
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2014 in British Journal of Cancer
Verified
Journal Article
Open access
OGon behalf of the PRECISION ITALIA STUDY GROUP
on behalf of the PRECISION ITALIA STUDY GROUP
Rita GolfieriRita Golfieri
Rita Golfieri
EGE Giampalma
E Giampalma
Matteo RenzulliMatteo Renzulli
Matteo Renzulli
RCR Cioni
R Cioni
FTF Trevisani
F Trevisani
Transcatheter arterial chemoembolisation (TACE) is the treatment of choice for intermediate stage hepatocellular carcinoma (HCC). Doxorubicin-loaded drug-eluting beads (DEB)-TACE is expected to improve the performance of conventional TACE (cTACE). The aim of this study was to compare DEB-TACE with cTACE in terms of time-to-tumour progression (TTP), adverse events (AEs), and 2-year survival. Patients were randomised one-to-one to undergo cTACE or DEB-TACE and followed-up for at least 2 years or until death. Transcatheter arterial chemoembolisation was repeated 'on-demand'. We enrolled 177 patients: 89 underwent DEB-TACE and 88 cTACE. The median number of procedures was 2 in each arm, and the in-hospital stay was 3 and 4 days, respectively (P=0.323). No differences were found in local and overall tumour response. The median TTP was 9 months in both arms. The AE incidence and severity did not differ between the arms, except for post-procedural pain, more frequent and severe after cTACE (P<0.001). The 1- and 2-year survival rates were 86.2% and 56.8% after DEB-TACE and 83.5% and 55.4% after cTACE (P=0.949). Eastern Cooperative Oncology Group (ECOG), serum albumin, and tumour number independently predicted survival (P<0.05). The DEB-TACE and the cTACE are equally effective and safe, with the only advantage of DEB-TACE being less post-procedural abdominal pain.

1 May 2016 in Radiology
Verified
Journal Article
Closed access
Matteo RenzulliMatteo Renzulli
Matteo Renzulli
SBStefano Brocchi
Stefano Brocchi
ACAlessandro Cucchetti
Alessandro Cucchetti
FMFederico Mazzotti
Federico Mazzotti
Cristina MosconiCristina Mosconi
Cristina Mosconi
Rita GolfieriRita Golfieri
Rita Golfieri
Some “worrisome” imaging features, such as nonsmooth tumor margins, peritumoral enhancement, two-trait predictor of venous invasion (“internal arteries” and “hypoattenuating halos”), and large tumor size were used to significantly predict the presence of microvascular invasion in hepatocellular carcinoma. PurposeTo determine the accuracy of imaging features, such as tumor dimension, multinodularity, nonsmooth tumor margins, peritumoral enhancement, and radiogenomic algorithm based on the association between imaging features (internal arteries and hypoattenuating halos) and gene expression that the authors called two-trait predictor of venous invasion (TTPVI), in the prediction of microvascular invasion (MVI) in hepatocellular carcinoma (HCC).Materials and MethodsThis single-center retrospective study was approved by the institutional review board, and the requirement for informed consent was waived. One hundred twenty-five patients (median age, 63 years; interquartile range, 53–71 years) with a diagnosis of HCC and indications for hepatic resection were included. Two observers independently reviewed radiologic images to evaluate the following features for MVI: maximum diameter, number of lesions, tumor margins, TTPVI, and peritumoral enhancement. Interobserver agreement was checked, and diagnostic accuracy...

5 February 2011 in European Radiology
Verified
Journal Article
Closed access
PDF file
Rita GolfieriRita Golfieri
Rita Golfieri
Matteo RenzulliMatteo Renzulli
Matteo Renzulli
VLVincenzo Lucidi
Vincenzo Lucidi
BCBeniamino Corcioni
Beniamino Corcioni
FTFranco Trevisani
Franco Trevisani
LBLuigi Bolondi
Luigi Bolondi

Verified
Journal Article
Open access
PDF file
KRKarim Rihawi
Karim Rihawi
ARAngela Dalia Ricci
Angela Dalia Ricci
Alessandro RizzoAlessandro Rizzo
Alessandro Rizzo
SBStefano Brocchi
Stefano Brocchi
Giovanni MarascoGiovanni Marasco
Giovanni Marasco
Matteo RenzulliMatteo Renzulli
Matteo Renzulli
Gastric cancer (GC) represents the fifth most frequently diagnosed cancer worldwide, with a poor prognosis in patients with advanced disease despite many improvements in systemic treatments in the last decade. In fact, GC has shown resistance to several treatment options, and thus, notable efforts have been focused on the research and identification of novel therapeutic targets in this setting. The tumor microenvironment (TME) has emerged as a potential therapeutic target in several malignancies including GC, due to its pivotal role in cancer progression and drug resistance. Therefore, several agents and therapeutic strategies targeting the TME are currently under assessment in both preclinical and clinical studies. The present study provides an overview of available evidence of the inflammatory TME in GC, highlighting different types of tumor-associated cells and implications for future therapeutic strategies.

3 February 2018 in Gut
Verified
Journal Article
Closed access
PDF file
Matteo RenzulliMatteo Renzulli
Matteo Renzulli
MBMaurizio Biselli
Maurizio Biselli
SBStefano Brocchi
Stefano Brocchi
AGAlessandro Granito
Alessandro Granito
FVFrancesco Vasuri
Francesco Vasuri
Rita GolfieriRita Golfieri
Rita Golfieri
Objective Many improvements have been made in diagnosing hepatocellular carcinoma (HCC), but the radiological hallmarks of HCC have remained the same for many years. We prospectively evaluated the imaging criteria of HCC, early HCC and high-grade dysplastic nodules (HGDNs) in patients under surveillance for chronic liver disease, using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) MRI and diffusion-weighted imaging. Design Our study population included 420 nodules >1 cm in 228 patients. The MRI findings of each nodule were collected in all sequences/phases. The diagnosis of HCC was made according to the American Association for the Study of Liver Diseases (AASLD) criteria; all atypical nodules were diagnosed using histology. Results A classification and regression tree was developed using three MRI findings which were independently significant correlated variables for early HCC/HCC, and the best sequence of their application in a new diagnostic algorithm (hepatobiliary hypointensity, arterial hyperintensity and diffusion restriction) was suggested. This algorithm demonstrated, both in the entire study population and for nodules ≤2 cm, higher sensitivity (96% [95% CI 93.5% to 97.6%] and 96.6% [95% CI 93.9% to 98.5%], P<0.001, respectively) and slightly lower specificity (91.8% [95% CI 88.6% to 94.1%], P=0.063, and 92.7% [95% CI 88.9% to 95.4%], P=0.125, respectively) than those of the AASLD criteria. Our new diagnostic algorithm also showed a very high sensitivity (94.7%; 95% CI 92% to 96.6%) and specificity (99.3%; 95% CI 97.7% to 99.8%) in classifying HGDN. Conclusion Our new diagnostic algorithm demonstrated significantly higher sensitivity and comparable specificity than those of the AASLD imaging criteria for HCC in patients with cirrhosis evaluated using Gd-EOB-DTPA MRI, even for lesions ≤2 cm. Moreover, this diagnostic algorithm allowed evaluating other lesions which could arise in a cirrhotic liver, such as early HCC and HGDN.

1 December 2012 in Journal of Hepatology
Verified
Journal Article
Closed access
ETE. Terzi
E. Terzi
Rita GolfieriRita Golfieri
Rita Golfieri
FPFabio Piscaglia
Fabio Piscaglia
MGM. Galassi
M. Galassi
ADA. Dazzi
A. Dazzi
LBL. Bolondi
L. Bolondi